GLPwatch
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
Lancet · 2023
Last updated 2026-07-17| Journal | Lancet, 2023 |
|---|---|
| Citations | 7 |
| Relative citation ratio | 0.68 |
| NIH percentile | 38 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Full record and abstract on PubMed 37385276 ↗